Maintenance therapy for advanced gastroesophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three medications: chemotherapy (paclitaxel) and two targeted/immunotherapy drugs (ramucirumab and tislelizumab) given after an initial 12-week treatment phase. The goal is to see if this maintenance therapy helps keep the cancer from growing and improves quality of life in people with advanced gastroesophageal cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have advanced (cannot be removed by surgery) or spread cancer in the esophagus or stomach.
- Your cancer is HER2-negative and has a PD-L1 score of 5 or higher (a protein level that makes the treatment more likely to work).
- You have not had treatment for this advanced cancer before (prior treatments before it spread are okay if more than 6 months ago).
- You are in good enough health to participate, with acceptable blood, kidney, and liver function.
- You are willing to give a tumor tissue sample and blood samples for research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests how well a tailored (response-adapted) chemotherapy plan works before surgery for stomach or gastroesophageal junction cancer. It aims to improve treatment planning while checking early safety.
This trial tests new combinations of drugs alongside standard chemotherapy for people with advanced stomach or esophagus cancer that has not been treated yet. It aims to see if these combinations can shrink tumors or slow down the cancer better than current options.
This study tests new drug combinations for people with advanced stomach or esophageal cancer that worsened after first treatment. It aims to find better options for those whose tumors lack HER2.
This trial tests a new combination of drugs for advanced stomach cancer that has spread or come back. It aims to see if adding an immune therapy and a bacterial extract to standard chemotherapy can help control the cancer better.
This trial tests a combination of two drugs, fruquintinib and a PD-1 inhibitor, as maintenance treatment after initial chemotherapy for advanced stomach or gastroesophageal junction cancer. It aims to see if this maintenance approach helps keep the cancer from growing. It is for patients with stable disease or better after first-line therapy.
This study tests two different treatment options for advanced stomach or gastroesophageal junction cancer that has grown after earlier chemotherapy. One option combines a targeted therapy (ramucirumab) with a chemotherapy pill (trifluridine/tipiracil), and the other is a standard chemotherapy drug (paclitaxel). The goal is to see which approach works better for people whose cancer has progressed, with the hope of improving outcomes.
Hear when a new Gastroesophageal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.